Maxacalcitol

Maxacalcitol

Maxacalcitol

Chemical compound

Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA).[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.[2]

Quick Facts Clinical data, Trade names ...

It was approved for use in Japan in 2010[3] and in Taiwan in 2018.[4]

References

  1. [1]
    Mizobuchi M, Ogata H (March 2014). "Clinical uses of 22-oxacalcitriol". Current Vascular Pharmacology. 12 (2): 324–328. doi:10.2174/15701611113119990023. PMID 23713875.
  2. [2]
    "Maxacalcitol". Inxight Drugs. National Center for Advancing Translational Sciences, U.S. National Institutes of Health.
  3. [3]
    "Maxacalcitol". New Drug Approvals in Japan. Kyoto Encyclopedia of Genes and Genomes. D01098.
  4. [4]
    Fukazawa-Shinotsuka M, Saito T, Abe M, Iida S, Wang IT, Terao K, et al. (January 2022). "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis". Drug Research. 72 (1): 23–33. doi:10.1055/a-1581-7609. PMID 34488237.
Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Maxacalcitol, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.